Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesReduction of serum prostate-specific antigen levels following varicella-zoster infection and valaciclovir treatment in prostate cancer
European Urology, 07/28/09
Jurhill RR et al. – In a case study of 2 prostate cancer (PCa) pts, 1 pt presented with a castration-resistant cancer and 1 with a temporary decrease in serum prostate-specific antigen (PSA) lasting for at least 4 mo.
Methods- 1 pt had a castration-resistant cancer whose rising serum PSA levels showed a remarkable drop after a reactivated varicella-zoster virus infection treated with valaciclovir.
- 1 pt had a temporary decrease in serum PSA lasting for at least 4 mo.
- In the pt with castration-resistant PCa, serum PSA decreased to <0.01 μg/l and has remained undetectable since.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life
Prostate Cancer & Prostatic Diseases, 11/30/09
The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study
European Urology, 11/30/09
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
Annals of Oncology, 11/24/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer
The Prostate, 11/30/09
Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life
Prostate Cancer & Prostatic Diseases, 11/30/09
Predicting Recurrence and Progression of Noninvasive Papillary Bladder Cancer at Initial Presentation Based on Quantitative Gene Expression Profiles
European Urology, 11/30/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Ultrasonic sonoporation can enhance the prostate permeability
Medical Hypotheses, 11/30/09
Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer
The Prostate, 11/30/09
Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life
Prostate Cancer & Prostatic Diseases, 11/30/09
Article Search
Sponsor